Specialty Pharmacy

Top news of the day across the health care landscape.

Researchers at Brigham and Women’s Hospital set out to evaluate the effects of switching insulins in those with type 2 diabetes.

The New Drug Application for upadacitinib is supported by data from the phase 3 SELECT trial program evaluating patients with moderate-to-severe rheumatoid arthritis.

Turoctocog alfa pegol, also known as N8-GP (Esperoct, Novo Nordisk), is indicated for adults and children with hemophilia A.

Pembrolizumab (Keytruda, Merck) is the first anti-PD-1 therapy approved in the adjuvant setting across patients with stage 3 melanoma.

Pembrolizumab (Keytruda) plus axitinib (Inlyta) was evaluated in a clinical trial of patients with clear-cell metastatic renal cell carcinoma.

Blocking the interaction between interleukin-33 and regulatory T cells may serve as a new therapeutic target for cancers associated with chronic inflammatory diseases.

Top news of the day across the health care landscape.

MDNA55 prolonged survival in IL4R-positive patients with recurrent glioblastoma in a phase 2b clinical trial.

The sBLA is based on data showing significant improvement in overall survival and progression-free survival in patients with advanced renal cell carcinoma.

Data from an analysis of multiple phase 3 studies highlight improvements in mobility, self-care, and usual activities for patients with moderate-to-severe psoriasis taking secukinumab (Cosentyx).

The study through Penn State College of Medicine adds to existing research on the benefits of medical cannabis in cancer cases.

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses the need for increased pharmacy benefit manager regulation on a federal level.

Top news of the day across the health care landscape.

A novel method of inactivating hepatitis C virus in donor lungs could increase transplantations for patients with end stage lung disease.

The ability to automate a medical benefit investigation is bringing new efficiencies to the hub and delivering better outcomes for providers, patients, and manufacturers.

Researchers have determined that many potentially adverse effects are not present on fact-based health care reviews.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Sofosbuvir-based regimens for the treatment of hepatitis C were well tolerated in Asian American communities, according to a new study.

A small mid-stage study demonstrated promising results for gene therapy candidate AMT-061 in patients with severe hemophilia B.

The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.

Top news of the day across the health care landscape.

African Americans are disproportionately affected by HIV infection in the United States.

Those with hepatitis B virus have a significantly elevated risk for developing any type of age-related macular degeneration, according to a new report

A new FDA program aims to facilitate better quality drug manufacturing through recognized consensus standards.

Phase 3 trial evaluating isatuximab in combination with standard of care met the primary endpoint of prolonging progression-free survival.